Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Clinical trial NCT00626795 · COMPLETED

Trial details

NCT number: NCT00626795
Sponsor: LEO Pharma
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Impetigo Secondarily Infected Traumatic Lesions

Start date: 2008-02-01
Primary completion: 2009-03-01
Enrollment: 773

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.